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Availability of healthcare resources and
epithelial ovarian cancer stage of diagnosis
and mortality among Blacks and Whites
Swati Sakhuja1, Huifeng Yun1,2, Maria Pisu2,3 and Tomi Akinyemiju1,2,4*

Abstract
Background: The purpose of this study is to examine whether racial disparities in epithelial ovarian cancer stage
at diagnosis and survival may be explained by geographic availability of healthcare resources among Blacks and
Whites.
Methods: Data from the Surveillance, Epidemiology and End Results (SEER) database was used to identify White
and Black women ages 40 years and above diagnosed with epithelial ovarian cancer between 2000 and 2010. Data
on county-level availability of healthcare resources was obtained from the Area Resource File. Multi-level regression
models, overall and stratified by race and age, were used to examine the associations of health care access (HCA)
and socioeconomic status (SES) with stage at diagnosis while Cox proportional hazards models were used to
examine the association with survival.
Results: Among 46,423 women diagnosed with epithelial ovarian cancer, Blacks were more likely to reside in
counties with fewer average number of oncology hospitals (p < 0.05) and hospitals with ultrasound (p < 0.001),
but higher number of medical doctors (p < 0.0001) and Ob/Gyn (p < 0.001). Black patients had higher odds of late
stage diagnosis of epithelial ovarian cancer (OR: 1.13, 95% CI: 1.04–1.25) and higher risk of epithelial ovarian cancer
mortality (HR: 1.25, 95% CI: 1.19–1.32) compared with White patients after accounting for differential availability of
healthcare resources. Among Black patients, residing in counties with fewer medical doctors was associated with
increased odds of late stage diagnosis (OR: 1.86, 95% CI: 1.10–3.13), and the racial disparity in late stage diagnosis
and mortality was larger among patients ages <65 years compared with older patients.
Conclusion: Racial disparities in availability and utilization of healthcare resources likely contributes to adverse
epithelial ovarian cancer outcomes among Black women in the US.
Keywords: Racial disparities, Ovarian cancer, Survival, Healthcare

Background
Ovarian cancer is the leading cause of death from
gynecological malignancies in the US [1, 2] and the fifth
most common cause of death among all cancer sites. [3, 4]
There are over 22,000 incident cases and 15,000 deaths
annually in the US, making it one of the most lethal
cancers for women. [3] Prognosis of ovarian cancer
mainly depends on stage at diagnosis, however screening
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for ovarian cancer has not been proven to be an effective
method for early detection. [5–7] Persistent racial, socioeconomic (SES) and healthcare access (HCA) disparities
exist in ovarian cancer outcomes, [8–10] suggesting that
there may be differential access to potentially life-saving
treatment strategies [11].
Studies examining disparities in ovarian cancer outcomes
have observed that while SES is significantly associated with
mortality, it does not fully explain racial disparities in
receipt of treatment or mortality. [12, 13] Beyond SES,
access to healthcare is another critical predictor of cancer
treatment and survival. Healthcare access comprehensively
defined incorporates aspects of availability, affordability,
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accommodation, acceptability and accessibility. [14]
Disparities in these components are also influenced by
other socio-cultural factors, and even in equal access
settings such as the Veteran’s Administration, racial
disparities in accessibility and utilization of cancer care
have been documented, [15–17] with Blacks more likely to
experience barriers to care and worse health outcomes [17].
Geographic access to healthcare and utilization of care
in relation to cancer outcomes is a relatively understudied and highly complex area of disparities research. It is
also an essential factor for early diagnosis and receipt of
high quality and timely treatment, elements critical for
the survival of women with ovarian cancer. [11, 18] Prior
studies have shown that the availability of healthcare
resources has significant influence on health outcomes,
including breast and colorectal cancer survival. [19–21]
The influence of healthcare availability on health outcomes also appears to vary by race; a higher number of
medical personnel and health facilities in US counties
was observed not to be significantly associated with reduced late stage presentation and longer survival for
Black colorectal cancer patients, but was associated
with improved outcomes for White colorectal cancer
patients. [19, 21] Since Black women are more likely to
present with late stage of disease and have higher mortality, despite lower ovarian cancer incidence compared
with Whites, [22–25] examining if and how availability
of healthcare resources influences ovarian cancer stage
and mortality among Blacks and Whites may improve
understanding of the causes of persistent racial disparities, while highlighting potential areas for targeted
intervention strategies.
In this paper, we examine racial disparities in availability of healthcare resources and association with epithelial
ovarian cancer stage at diagnosis and survival among
Blacks and Whites in the US.

Methods
Data Source and Study population: Data for this study
was obtained from the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) program using
the SEER 18 Registries (excluding AK and Louisiana), Nov
2012 Submission - linked To County Attributes - Total
U.S., 1969–2011 Counties plus Area Resource File (ARF2008). SEER covers about 28% of the U.S. population, and
includes detailed information for each cancer diagnosis on
demographics, disease stage, histology, surgery of primary
site, vital status and survival months. Eligibility criteria for
this study includes White and Black adult women ages
40 years and above with a primary diagnosis of epithelial
ovarian cancer represented in the registry and diagnosed
between 2000 and 2010.
Outcome Variables: There were two primary outcomes
of interest in this study: 1) Stage at diagnosis (excluding
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in situ cases), defined as late stage (if distant) or early
stage (if localized or regional) using SEER summary
stage 2000 (1998+) variable; and 2) Survival defined as
time in months from diagnosis to death due to epithelial
ovarian cancer as identified in the SEER database.
Health Care Availability (HCA): Data on county level
healthcare resources was obtained from the Area Health
Resource File (AHRF) developed by the U.S Health Resources and Services Administration. Details can be obtained from: http://ahrf.hrsa.gov. We defined HCA using
the following variables for the year 2005 per million
population: number of hospitals, number of hospitals
with oncology services, number of hospitals with ultrasound services, number of Obstetricians/Gynecologists
(OB/GYN), and number of physicians. The percent of
individuals who have no health insurance was also included in the analysis, as this may influence the concentration of hospitals, clinics or medical personnel in particular
neighborhoods. County level data was utilized for this
study since decisions on the location of healthcare resources such as hospitals and clinics often are often made
at the county and/or municipal level.
Study Covariates: County level SES was included in
the analysis and defined based on: percent of population
with less than a 9th grade education and percent of families living below the federal poverty level for the year
2000. Individual level data on histologic type using International Classification of Diseases for Oncology, Third
Edition (ICD-O-3) codes [26]) and primary site-specific
surgery were also included in the analysis as dichotomous
variables based on information in the SEER database. The
analysis focused on epithelial ovarian cancer, and other
less common subtypes were excluded for analysis based
on ICD-O-3 codes (i.e., 8000–8004, 8240–8245, 8590–
8670, 8800–8951 and 9060–9975).
Statistical analysis: We compared the distribution of
socio-demographic, clinical, histologic and county-level
HCA by race/ethnicity using chi-Square tests for categorical variables and analysis of variance test (ANOVA)
for continuous variables. We first examined whether racial differences existed between Blacks and Whites in
epithelial ovarian cancer stage at diagnosis and survival
after adjusting for demographic, clinical, HCA and SES
variables. We formally assessed for effect modification
by including interaction terms for race and HCA, and
age and HCA. Next, we conducted race- and age- stratified analysis to determine whether HCA variables were
associated with stage or survival in both racial groups
and by age-group. This allowed us to examine whether
racial disparities existed in epithelial ovarian cancer outcomes among women <65 years (who are more likely to
have private insurance and Medicaid) and those >65 years
(who are eligible for Medicare insurance). To examine
racial differences in epithelial ovarian cancer stage, we
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Table 1 Socio-demographic and healthcare access characteristics of epithelial ovarian cancer patients by race/ethnicity, SEER 2000–2010
Characteristics

Blacks 3219 (6.90%)

Whites 43,204 (93.07%)

P-value

40–54

876 (27.21)

10,865 (25.15)

<0.0001

55–64

847 (26.31)

10,923 (25.28)

65–74

762 (23.67)

9746 (22.56)

75+

734 (22.80)

11,670 (27.01)

Yes

2483 (75.74)

30,322 (70.18)

No

781 (24.26)

12,882 (29.82)

Yes

1963 (60.98)

33,253 (76.97)

No

1227 (38.12)

9676 (22.40)

29 (0.90)

275 (0.64)

Demographics and clinical characteristics
Age at Diagnosis (years)

Late Stage
<0.0001

Site-specific Surgery

Unknown
Deatha

<0.0001

<0.0001

Yes

1574 (58.96)

19,355 (50.72)

No

1051 (40.04)

18,803 (49.28)

County-Level Healthcare Availability
% Uninsured
Mean (SD)
< 25th percentile

15.91 (4.07)

15.17 (4.84)

<0.0001

439 (13.64)

10,813 (25.03)

<0.0001

25-75th percentile

1994 (61.94)

21,688 (50.21)

> 75th percentile

786 (24.40)

10,697 (24.76)

16.56 (13.57)

16.80 (17.69)

0.6545

< 25th percentile

403 (12.52)

8782 (20.33)

<0.0001

25-75th percentile

1909 (59.03)

23,590 (54.61)

> 75th percentile

907 (28.18)

10,826 (25.06)

b

Hospitals

Mean (SD)

b

Oncology

Mean (SD)
< 25th percentile

7.00 (5.40)

7.32 (10.25)

910 (28.27)

12,920 (29.91)

0.0078
<0.0001

25-75th percentile

962 (29.89)

18,343 (42.46)

> 75th percentile

1347 (41.85)

11,935 (27.63)

1101.16 (545.33)

934.27 (557.10)

<0.0001

< 25th percentile

499 (15.50)

10,727 (24.83)

<0.0001

25-75th percentile

1641 (50.98)

21,873 (50.63)

> 75th percentile

1079 (33.52)

10,598 (24.53)

b

Medical Doctors

Mean (SD)

b

OB/GYN

Mean (SD)
< 25th percentile

157.29 (84.84)

127.51 (69.43)

<0.0001

422 (13.11)

10,572 (24.47)

<0.0001

25-75th percentile

1663 (51.66)

22,808 (52.80)

> 75th percentile

1134 (35.23)

9818 (22.73)

9.56 (11.36)

10.81 (15.54)

b

Hospitals with Ultrasound

Mean (SD)

<0.0001

Sakhuja et al. Journal of Ovarian Research (2017) 10:57

Page 4 of 10

Table 1 Socio-demographic and healthcare access characteristics of epithelial ovarian cancer patients by race/ethnicity, SEER 2000–2010
(Continued)
< 25th percentile

625 (19.42)

9502 (22.00)

25-75th percentile

1890 (58.71)

23,262 (53.85)

> 75th percentile

704 (21.87)

10,434 (24.15)

<0.0001

County-Level Socioeconomic Status
% Less than 9th Grade Education
Mean (SD)
< 25th percentile

8.56 (4.26)

8.40 (4.86)

355 (11.03)

11,461 (26.53)

0.0209
<0.0001

25-75th percentile

2053 (63.78)

21,040 (48.71)

> 75th percentile

811 (25.19)

10,697 (24.76)

10.62 (4.31)

8.77 (4.50)

<0.0001

< 25th percentile

438 (13.61)

11,232 (26.00)

<0.0001

25-75th percentile

1398 (43.43)

22,110 (51.18)

> 75th percentile

1383 (42.96)

9856 (22.82)

% Families below poverty level
Mean (SD)

a

Ovarian cancer specific deaths only
b
per million population
Late stage defines as distant metastasis at presentation
Bold indicates significance (p value <0.05)

conducted consecutive multilevel regression model
which allowed us to include random effects into the
model thereby accounting for between-county variation
and within-county correlation. To examine racial differences in epithelial ovarian cancer survival, we examined
time to ovarian cancer-related deaths using Cox proportional hazards models adjusting for both individual
level (demographics, clinical) and county level (HCA,
SES) variables and accounted for clustering. Patients
were censored at the time of death, or end of follow-up
(December 2013). Further, we assessed proportionality
of hazards by plotting survival curves and using a time
dependent predictor in the hazards model. All statistical analyses were conducted using SAS version 9.4.

Results
There were 46,423 Black and White women with epithelial ovarian cancer diagnosed from 2000 to 2010 in the
SEER registry. Among these patients, 93.1% were White
and 6.9% were Black (Table 1). Blacks were more likely
to be diagnosed with epithelial ovarian cancer at a younger age compared with Whites (Blacks: 27.2%, Whites:
25.2% ages 40–54, p-value: < 0.0001). Blacks were less
likely to undergo site-specific surgery for epithelial
ovarian cancer as compared to Whites (61.0% vs. 77.0%,
p-value: <0.0001). Black patients were more likely to live
in counties with greater number of medical doctors (1101
vs. 934, p-value: < 0.0001), counties with greater number
of Ob/Gyn (157 vs. 127, p-value: < 0.0001), but counties
with fewer numbers of hospitals with ultrasound machines
(9.6 vs. 10.8, p-value: < 0.0001) compared with Whites. In

addition, Black patients were more likely to reside in
counties with a higher proportion of families living below
the poverty level (43.0% vs. 22.8%, p-value: < 0.0001) compared with White patients.
In multivariable adjusted models with HCA variables
(Table 2), Blacks had 13% higher odds for late stage
diagnosis of epithelial ovarian cancer (OR: 1.13, 95% CI:
1.04–1.25) compared with Whites. In the model adjusting for both HCA and SES, Blacks remained at 14%
higher odds of late stage diagnosis (OR: 1.14, 95% CI:
1.04–1.25) and the interaction between race and number
of medical doctors in the county was statistically significant (p value = 0.0354). Additionally, epithelial ovarian
cancer mortality was 25% higher among Blacks compared
with Whites in adjusted models with HCA variables (HR:
1.25, 95% CI: 1.19–1.32) as well as HCA and SES adjusted
model (HR: 1.24, 95% CI: 1.18–1.31). Residing in counties
with fewer medical doctors was independently associated
with increased risk for mortality (HR: 1.12, 95% CI: 1.04–
1.20) and this association remained after additionally
adjusting for SES (HR: 1.11, 95% CI: 1.03–1.20). Further,
there was also a significant linear trend in the association
between in-county number of medical doctors and epithelial ovarian cancer mortality (p value: <0.0001).
Among Black patients (Table 3), residing in counties
with fewer medical doctors was associated with 86% increased odds of late stage diagnosis in the HCA only
model (OR: 1.86, 95% CI: 1.10–3.13) and almost doubled
the odds in the HCA and SES model (OR: 1.91, 95% CI:
1.13–3.24) compared with residing in the highest quartile.
There were no significant associations between HCA and
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Table 2 Multivariable adjusted analysis for late-stage epithelial ovarian cancer diagnosis and mortality, SEER 2000–2010
Late Stage Diagnosis AOR (95% CI)

Mortality AHR (95% CI)c

Odds Ratio

Hazard Ratio

HCA Onlya

HCA and SESb

HCA Onlya

HCA and SESb

Race
Blacks

1.13 (1.04–1.25)

1.14 (1.04–1.25)

1.25 (1.19–1.32)

1.24 (1.18–1.31)

Whites

Ref

Ref

Ref

Ref

Healthcare Availability
% Uninsured
< 25th percentile

0.98 (0.89–1.08)

1.02 (0.93–1.13)

0.95 (0.91–1.00)

1.00 (0.94–1.07)

25 – 75th percentile

1.06 (0.93–1.08)

1.02 (0.93–1.13)

0.94 (0.91–0.98)

0.98 (0.93–1.04)

> 75th percentile

Ref

Ref

Ref

Ref

# Hospitals
< 25th percentile

1.01 (0.92–1.11)

1.04 (0.94–1.14)

0.95 (0.89–1.00)

0.96 (0.90–1.02)

25 – 75th percentile

1.00 (0.92–1.08)

0.99 (0.91–1.07)

0.99 (0.94–1.04)

1.00 (0.95–1.05)

> 75th percentile

Ref

Ref

Ref

Ref

# Oncology Hospitals
< 25th percentile

0.95 (0.87–1.03)

0.98 (0.90–1.07)

0.95 (0.91–1.00)

0.96 (0.91–1.02)

25 – 75th percentile

0.98 (0.92–1.05)

0.99 (0.93–1.06)

0.97 (0.93–1.01)

0.97 (0.93–1.01)

> 75th percentile

Ref

Ref

Ref

Ref

# Medical Doctorsd
< 25th percentile

1.10 (0.97–1.25)

1.10 (0.97–1.25)

1.12 (1.04–1.20)

1.11 (1.03–1.20)

25 – 75th percentile

1.07 (0.97–1.18)

1.07 (0.97–1.18)

1.06 (1.002–1.12)

1.05 (0.99–1.12)

> 75th percentile

Ref

Ref

Ref

Ref

< 25th percentile

0.86 (0.76–0.98)

0.84 (0.74–0.95)

1.01 (0.94–1.09)

1.01 (0.93–1.09)

25-75th percentile

0.89 (0.81–0.99)

0.87 (0.78–0.96)

1.01 (0.95–1.07)

1.01 (0.95–1.08)

> 75th percentile

Ref

Ref

Ref

Ref

< 25th percentile

1.05 (0.94–1.17)

1.02 (0.92–1.14)

1.00 (0.94–1.07)

1.00 (0.94–1.07)

25-75th percentile

0.99 (0.91–1.08)

0.99 (0.91–1.08)

0.97 (0.92–1.02)

0.96 (0.91–1.01)

> 75th percentile

Ref

Ref

Ref

Ref

# OB/GYN

# Hospitals with Ultrasound

a

Adjusted for county level HCA variables, age, surgery of primary site and seer registry
b
Adjusted for county level HCA and SES variables, age, surgery of primary site and seer registry
c
Additionally adjusted for late stage diagnosis
d
Linear trend test with ovarian cancer mortality was significant at p < 0.0001 level
# Number per million population

odds of late stage diagnosis among Whites. There were
also no significant associations with epithelial ovarian cancer mortality in the HCA and SES models for Blacks.
However, Whites residing in counties with fewer medical
doctors experienced a 12% increased risk of epithelial
ovarian cancer mortality in the HCA only (HR: 1.12, 95%
CI: 1.04–1.21) and HCA and SES (HR: 1.12, 95% CI: 1.03–
1.21) models (Table 4).
Among patients <65 years (Table 5), Blacks had a 20%
higher odds of late stage diagnosis compared with Whites
(OR: 1.20, 95% CI: 1.07–1.35), however, there was no racial difference in stage at diagnosis observed among

patients ages 65 years and older. Although, women
65 years and older residing in county with fewer medical
doctors had higher odds for late stage diagnosis compared
to those living in county with higher number of medical
doctors (OR: 1.29, 95% CI: 1.06–1.58), this association was
reversed for those residing in counties with fewer number
of Ob/Gyn (OR: 0.74, 95% CI: 0.61–0.90). Blacks had
higher risk for epithelial ovarian cancer mortality than
Whites in both age groups (<65 years HR: 1.27, 95% CI:
1.17–1.37) and (65 years and older HR: 1.14, 95% CI:
1.06–1.22), although the disparity was larger in the
<65 years age group.
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Table 3 Multivariable adjusted odds ratios for late-stage epithelial ovarian cancer diagnosis by race, SEER 2000–2010
Blacks AOR (95% CI)
HCA Only

a

p-interactionc

Whites AOR (95% CI)
HCA and SES

b

HCA Only

a

b

HCA and SES

Healthcare Availability
% Uninsured
< 25th percentile

0.1014
0.76 (0.753–1.08)

0.82 (0.48–1.40)

1.00 (0.94–1.09)

1.02 (0.88–1.17)

25 – 75th percentile

1.03 (0.79–1.34)

0.99 (0.66–1.49)

1.01 (0.94–1.09)

1.03 (0.93–1.14)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

1.08 (0.71–1.63)

1.23 (0.78–1.92)

1.01 (0.92–1.11)

1.03 (0.93–1.14)

# Hospitals
< 25th percentile

0.7025

25 – 75th percentile

1.14 (0.82–1.60)

1.15 (0.82–1.61)

0.99 (0.91–1.08)

0.98 (0.90–1.06)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

0.90 (0.64–1.26)

0.97 (0.68–1.39)

0.95 (0.87–1.04)

0.97 (0.89–1.07)

# Oncology Hospitals
< 25th percentile

0.6876

25 – 75th percentile

1.13 (0.87–1.48)

1.25 (0.93–1.68)

0.97 (0.91–1.04)

0.98 (0.91–1.05)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

< 25th percentile

1.86 (1.10–3.13)

1.91 (1.13–3.24)

1.06 (0.93–1.21)

1.06 (0.93–1.21)

25 – 75th percentile

1.53 (1.10–2.12)

1.57 (1.12–2.19)

1.03 (0.93–1.14)

1.03 (0.93–1.15)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

< 25th percentile

0.67 (0.40–1.13)

0.61 (0.35–1.05)

0.88 (0.78–1.00)

0.86 (0.75–0.98)

25-75th percentile

0.68 (0.49–0.95)

0.62 (0.43–0.88)

0.91 (0.82–1.01)

0.89 (0.80–0.99)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

1.05 (0.69–1.60)

1.05 (0.68–1.61)

1.05 (0.94–1.17)

1.03 (0.92–1.15)

# Medical Doctors

0.0354

# OB/GYN

0.3754

# Hospitals with Ultrasound
< 25th percentile

0.7730

25-75th percentile

0.94 (0.68–1.28)

0.94 (0.68–1.29)

0.99 (0.90–1.08)

0.99 (0.91–1.09)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

a

Adjusted for age, surgery of primary site and seer registry
Additionally adjusted for SES variables
c
For interaction terms between race and each HCA variable
# Number per million population
Bold indicates significance (p value ≤0.05)
b

Discussion
Using the population-based SEER registry to analyze data
on epithelial ovarian cancer patients and linked county
level information on availability of healthcare resources
and SES, we observed significant racial differences in the
availability of healthcare resources among epithelial ovarian cancer patients in the US. Compared to White patients, Black patients resided in counties with lower health
insurance coverage, fewer numbers of oncology hospitals,
and fewer numbers of hospitals with ultrasound machines.
However, they resided in counties with a higher number
of medical doctors and OB/Gyn specialists. We observed
that accounting for these differences, in addition to clinical
and histologic variables, did not eliminate racial disparities in late stage diagnosis or mortality with epithelial
ovarian cancer, even though timely diagnosis and high-

quality treatment of epithelial ovarian cancer are most
likely dependent on specialty-trained surgeons and
healthcare centers with multidisciplinary oncologic care
and ultrasound equipment. [27, 28] We observed that
among Blacks, residing in counties with fewer medical
doctors doubled the odds of late stage diagnosis, however,
none of the HCA variables were independently associated
with stage at diagnosis for Whites. In contrast, none of the
HCA variables independently predicted epithelial ovarian
cancer mortality among Blacks, but residing in counties
with fewer medical doctors was associated with increased
risk of epithelial ovarian cancer mortality among Whites.
These results suggest that access to healthcare is a much
more complex issue beyond only availability of resources, and racial differences may exist in terms of
other aspects of access to care, e.g., accessibility,
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Table 4 Multivariable adjusted hazards ratios for epithelial ovarian cancer mortality by race, SEER 2000–2010
Blacks AHR (95% CI)
HCA Only

a

p-interactionc

Whites AHR (95% CI)
HCA and SES

b

HCA Only

a

b

HCA and SES

Healthcare Availability
% Uninsured
< 25th percentile

0.3326
1.12 (0.90–1.38)

1.24 (0.91–1.68)

0.95 (0.90–0.99)

1.00 (0.93–1.07)

25 – 75th percentile

1.11 (0.95–1.29)

1.08 (0.86–1.35)

0.94 (0.90–0.97)

0.98 (0.93–1.03)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

0.73 (0.57–0.94)

0.83 (0.63–1.08)

0.96 (0.90–1.02)

0.97 (0.91–1.03)

# Hospitals
< 25th percentile

0.1093

25 – 75th percentile

0.94 (0.77–1.14)

0.95 (0.78–1.16)

0.99 (0.94–1.05)

1.00 (0.95–1.05)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

0.92 (0.76–1.12)

0.94 (0.76–1.16)

0.96 (0.91–1.01)

0.97 (0.91–1.02)

# Oncology Hospitals
< 25th percentile

0.5587

25 – 75th percentile

1.12 (0.96–1.31)

1.13 (0.95–1.34)

0.96 (0.92–1.00)

0.97 (0.93–1.01)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

1.20 (0.88–1.63)

1.18 (0.87–1.61)

1.12 (1.04–1.21)

1.12 (1.03–1.21)

# Medical Doctors
< 25th percentile

0.8371

25 – 75th percentile

1.02 (0.84–1.24)

1.04 (0.85–1.26)

1.07 (1.01–1.14)

1.06 (0.997–1.13)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

1.02 (0.75–1.39)

1.00 (0.72–1.38)

1.01 (0.93–1.08)

1.00 (0.92–1.09)

# OB/GYN
< 25th percentile

0.8834

25-75th percentile

1.08 (0.89–1.31)

1.04 (0.85–1.27)

1.00 (0.94–1.07)

1.01 (0.94–1.08)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

1.06 (0.83–1.36)

1.05 (0.82–1.35)

1.00 (0.93–1.07)

0.99 (0.93–1.07)

# Hospitals with Ultrasound
< 25th percentile

0.5357

25-75th percentile

0.95 (0.79–1.13)

0.94 (0.79–1.13)

0.97 (0.92–1.02)

0.96 (0.91–1.01)

> 75th percentile (Ref)

Ref

Ref

Ref

Ref

a

Adjusted for age, surgery of primary site, late stage diagnosis and seer registry
Additionally adjusted for county level SES variables
c
For interaction terms between race and each HCA variable
# Number per million population
Bold indicates significance (p value ≤0.05)
b

availability, affordability, accommodation and acceptability, with potentially significant consequences for epithelial
ovarian cancer outcomes as well as racial disparities.
Ovarian cancer is one of the most lethal gynecologic
cancers [2] with 5-year survival rates of less than 50%
after initial diagnosis. [4] Early diagnosis when the tumor is
localized to the ovaries is the most important prognostic
factor in treatment planning and improvement of survival
of these patients. [4, 29] However, early diagnosis of ovarian
cancer remains difficult as the disease is often asymptomatic [30] or presents with non-specific symptoms such as
back pain, fatigue, constipation or abdominal pain/bloating,
which are rarely gynecologic in nature. [31–33] Routine
screening for ovarian cancer is currently not recommended
except for high-risk groups of women with a genetic predisposition or family history of ovarian or breast cancer. [34]
However, a study by Smith et al. using the Medicare linked

California SEER database showed that women ages 68 years
and older with recent diagnosis of ovarian cancer were
more likely to have received clinical evaluations for
non-specific abdominal symptoms 6 months before the
diagnosis. [35] As ovarian cancer progresses very rapidly
[36], this window may be especially crucial in early detection of ovarian cancer. Despite the current lack of highly
sensitive screening approaches, improved access to healthcare resources is still a critical factor in early diagnosis
and timely and accurate treatment of ovarian cancer, as
specialized physicians and ultrasound imaging will be
required for definitive diagnosis, timely treatment and
improved outcomes.
Differential access to high quality healthcare remains a
significant public health issue and contributes to sustained racial differences in cancer outcomes. Other studies have shown that multiple factors beyond individual
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Table 5 Age-stratified multivariable adjusted analysis for late-stage epithelial ovarian cancer diagnosis and mortality,
SEER 2000–2010
Late Stage Diagnosis AOR (95% CI)

p-interactionb

Mortality AHR (95% CI)a

<65 years

> = 65 years

<65 years

> = 65 years

Blacks

1.20 (1.07–1.35)

1.00 (0.87–1.15)

1.27 (1.17–1.37)

1.14 (1.06–1.22)

Whites

Ref

Ref

Ref

Ref

< 25th percentile

0.96 (0.82–1.13)

0.96 (0.78–1.18)

1.04 (0.94–1.16)

0.99 (0.91–1.08)

25 – 75th percentile

1.01 (0.90–1.13)

1.02 (0.88–1.18)

1.02 (0.94–1.11)

0.97 (0.90–1.03)

> 75th percentile

Ref

Ref

Ref

Ref

< 25th percentile

1.11 (0.98–1.26)

0.94 (0.81–1.10)

0.99 (0.90–1.10)

0.92 (0.85–1.00)

25 – 75th percentile

1.03 (0.93–1.14)

0.93 (0.82–1.06)

0.97 (0.90–1.05)

1.01 (0.95–1.07)

> 75th percentile

Ref

Ref

Ref

Ref

< 25th percentile

0.97 (0.87–1.08)

1.01 (0.89–1.16)

0.98 (0.90–1.06)

0.94 (0.87–1.00)

25 – 75th percentile

0.99 (0.91–1.08)

1.03 (0.92–1.14)

0.95 (0.89–1.01)

0.99 (0.94–1.05)

> 75th percentile

Ref

Ref

Ref

Ref

1.00 (0.86–1.17)

1.29 (1.06–1.58)

1.15 (1.03–1.30)

1.06 (0.96–1.17)

p-interactionc

Race

Healthcare Availability
% Uninsured

0.5071

# Hospitals

0.8476

# Oncology Hospitals

0.2352

0.4025

# Medical Doctors
< 25th percentile

0.6687

0.4809

0.3598

0.8026

25 – 75th percentile

0.98 (0.87–1.11)

1.24 (1.07–1.45)

1.12 (1.02–1.23)

1.00 (0.93–1.08)

> 75th percentile

Ref

Ref

Ref

Ref

0.90 (0.77–1.06)

0.74 (0.61–0.90)

0.95 (0.84–1.08)

1.03 (0.94–1.14)

25-75th percentile

0.96 (0.84–1.09)

0.76 (0.65–0.89)

0.95 (0.86–1.05)

1.04 (0.96–1.13)

> 75th percentile

Ref

Ref

Ref

Ref

< 25th percentile

1.00 (0.87–1.15)

1.03 (0.87–1.22)

0.93 (0.84–1.03)

1.07 (0.99–1.17)

25-75th percentile

0.97 (0.87–1.09)

1.00 (0.87–1.15)

0.97 (0.89–1.05)

0.95 (0.88–1.01)

> 75th percentile

Ref

Ref

Ref

Ref

# OB/GYN
< 25th percentile

0.4963

# Hospitals with Ultrasound

0.9950

0.9655

0.1684

Adjusted for county level HCA and SES variables, age, surgery of primary site and seer registry
a
Additionally adjusted for late stage diagnosis
b
For interaction terms between age and each HCA variable with late stage diagnosis as outcome
c
For interaction terms between age and each HCA variable with ovarian cancer mortality as outcome
# Number per million population
Bold indicates significance (p value ≤0.05)

health insurance status contribute to healthcare accessibility and utilization, including factors relating to quantity,
quality, distance, as well as cultural attitudes towards
healthcare. [37–40] Tracey et al. showed that that women
with ovarian cancer treated in public general hospitals had
higher mortality rates compared to those who were treated
at a gynecological oncology service, and that distance from
the specialized hospital played an important role in the decision making process for where to receive treatment. [41]
Other studies have also demonstrated persistent racial disparities in equal access settings such as the VA system and
other population based cohorts like Kaiser Permanente-

Research on Ovarian Cancer Survival (KP-ROCS) Cohort
Study, with Blacks less likely to receive cancer treatment
and more likely to die due to their disease compared with
other racial groups. [17, 42] In the current study, we found
that epithelial ovarian cancer mortality in Blacks was significantly higher than in Whites, consistent with previous
studies. [13, 43] However, we did not find significant associations between any HCA variable and epithelial ovarian
cancer mortality among Blacks, although reduced number
of medical personnel at the county level was associated
with higher mortality among Whites. This suggests that
interventions to increase availability of medical doctors
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may help to improve epithelial ovarian cancer outcomes
among Whites, while more work is needed to identify
factors that mediate the association between availability
of healthcare resources, utilization of such resources
and epithelial ovarian cancer outcomes among Blacks.
The strength of the study is the use of the populationbased SEER registry to assess epithelial ovarian cancer
outcomes and examination of county-level availability of
healthcare resources and socio-economic status among
Black and White women, the two racial groups with
the largest disparity. The analysis is strengthened by
the use of multi-level modeling to account for correlations
between individuals residing in the same county. The
analysis focused on the most common subtype of ovarian cancer- epithelial ovarian cancer- which accounted
for 86% of cases in Blacks and 90% of cases in Whites,
and we observed consistent results when additionally
adjusted for histology. There are also several limitations
in this study. First, the use of a county as a geographic
unit, which is a relatively large geographical area may
have resulted in residual confounding if county availability
of health care resources does not fully capture the variation in HCA available to individuals. However, analysis of
major community resources such as hospitals usually
requires larger geographic units of analysis, as they are
primarily considered at the municipal, county or state
level, and considering smaller geographic areas would
have resulted in a large number of geographic regions
with missing data. Second, we were unable to adjust
for individual level SES variables since these are not
present in the SEER database, and instead included
area level SES in our models. Further, SEER does not
include data on comorbidities, which precluded us from
accounting for differential health status of patients at
diagnosis which may impact mortality. Lastly, the SEER
registry does not provide detailed data on adjuvant
chemotherapy or detailed information on timing of surgery, and we also lacked data on the presence of residual disease following debulking or cytoreductive
surgery. Due to these limitations, we were unable to account for potential racial differences in the quality of
actual treatment received, another important factor for
survival although we were able to adjust for the receipt
of site-specific surgery.

Conclusion
In conclusion, this study provides evidence that racial/
ethnic disparities exist in the availability of healthcare resources among epithelial ovarian cancer patients, and
these influence stage of diagnosis and survival. For Black
patients, more research is needed to better understand
the factors predicting utilization of existing healthcare
resources, and if these influence healthcare outcomes.
Further research on other dimensions of healthcare
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access such as acceptability, accessibility and affordability may inform efforts to increase utilization of existing resources among Black and White cancer patients,
eliminating the persistent racial disparity in late stage diagnosis, and ultimately improving survival for all patients.
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